Unknown

Dataset Information

Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.


ABSTRACT:

Background

Hyperammonemia can result in hepatic encephalopathy, which in severe cases eventually can lead to coma and death. In dogs, congenital portosystemic shunts (CPSS) are the most common cause for hyperammonemia. Conservative treatment consists of a protein modified diet, nonabsorbable disaccharides, antibiotics, or some combinations of these. Sodium benzoate (SB) and sodium phenylbutyrate (SPB) both are used in the acute and long-term treatment of humans with hyperammonemia caused by urea cycle enzyme deficiencies. Both treatments are believed to lower blood ammonia concentrations by promoting excretion of excess nitrogen via alternative pathways.

Objectives

To evaluate the efficacy and safety of PO treatment with SB and SPB on hyperammonemia and clinical signs in CPS

SUBMITTER: van Straten G 

PROVIDER: S-EPMC6524074 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature